Enshorx
Morris Plains, US · 2 known investors
Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.
Founders & leadership
NB
Neena Bitritto-GargFounder
GH
Gerhard HagnChief Executive Officer
DF
Danielle FryChief Operating Officer and Chief Legal Officer
TT
Tory TrippeVice President, Head of Finance and Corporate Development
MR
Matthew R. WarrSenior Vice President, Research & Head of Biology
AW
Andy WhitneyChief Scientific Officer
Investors · 2
Frequently asked questions
- What does Enshorx do?
- Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.
- Who founded Enshorx?
- Enshorx was founded by Neena Bitritto-Garg.
- Who are Enshorx's investors?
- Enshorx's investors include Avego BioScience Capital, Global BioAccess Fund.
- Where is Enshorx headquartered?
- Enshorx is headquartered in Morris Plains, US.